JAVELIN PHARMACEUTIC (AMEX:JAV)

Headlines for JAVELIN PHARMACEUTIC

Javelin Pharmaceuticals Reports Fiscal Results for the Year Ended 2009
Business Wire - 21 hours ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (NYSE - Amex: JAV) recently reported its audited financial results for the full year and quarter ending December 31, 2009. -- On ...
Javelin Pharma Q4 Loss Narrows - RTT News
Millennium Reveals 7% or $6.5M Stake in Javelin - CBL
www.citybizlist.com - Mar 5, 2010
By Citybizlist Staff CAMBRIDGE -- In a filing with the SEC, Millennium Management LLC has revealed a 7% stake in pain management company Javelin Pharmaceuticals Inc. New York-based Millennium owns ...
NY firm buys 7% stake in Javelin Pharma
Boston Business Journal - Mar 4, 2010
Millennium Management, a New York-based investment firm, has acquired a 7 percent stake in Javelin Pharmaceuticals Inc., the Cambridge, Mass.-based drug developer that is slated to merge with Utah ...
Javelin Pharmaceuticals’ Receives FDA PDUFA Date For Dyloject™ NDA
TheStreet.com - Feb 17, 2010
By Business Wire 02/17/10 - 08:55 AM EST Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today announced ...
Javelin Pharma (JAV) US FDA NDA for Dyloject Receives PDUFA Date of October 3, 2010 - StreetInsider.com
Javelin Pharmaceuticals' Dyloject NDA receives FDA PDUFA date - News-Medical.net